Detecting urinary exosomes in patients with clear cell renal cell carcinoma
Official title: Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma
Run by Centre Hospitalier Universitaire de Saint Etienne · NCT04053855 · Data updated 2026-11-12
This study is testing a new way to find cancer markers in urine from patients with clear cell kidney cancer to see if it can help with early diagnosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne Academic / other |
| Locations | 1 site (Saint-Etienne) |
| Status | Recruiting |
| Started | January 29, 2020 |
| Main results expected | August 1, 2026 |
| Study ends | August 1, 2026 |
| Registry record updated | May 6, 2026 |
| Trial ID | NCT04053855 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with a renal mass requiring surgical intervention, such as partial or total nephrectomy.
✕Probably not a fit
Patients with insufficient urine sample volume or those with urinary catheters may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to develop a reliable technique for detecting urinary exosomes in patients diagnosed with clear cell renal cell carcinoma. By utilizing electron microscopy and flow cytometry, the study will analyze urine samples to identify specific exosome markers associated with the cancer. The goal is to create a non-invasive biological test that could facilitate early diagnosis, potentially improving patient outcomes. The study will include patients undergoing nephrectomy for renal masses and will compare their urinary exosome profiles to those of control patients.
Why it matters
Potential benefit: If successful, this study could lead to a simple and non-invasive method for the early diagnosis of clear cell renal cell carcinoma.
How similar studies have gone: While the use of urinary exosomes for cancer detection is a promising area, this specific approach is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients: * All patients with renal mass requiring surgery (partial or total nephrectomy) * Social security affiliation * Signed informed consent Control : * Unscheduled nephrectomy * Social security affiliation * Signed informed consent Exclusion Criteria: * Insufficient volume of urine sample (\< 100 ml) * Patients with a urinary catheter * Patients under court-ordered guardianship or curators
Where it's running
-
Chu Saint-Etienne
Saint-Etienne, France Recruiting
Study contacts
- Principal investigator: Nicolas MOTTET, MD PhD — Centre Hospitalier Universitaire de Saint Etienne
- Study coordinator: Nicolas MOTTET, MD PhD
- Email: nicolas.mottet@chu-st-etienne.fr
- Phone: (0)477828331
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cadonilimab and Lenvatinib in advanced kidney cancer
This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.
-
CAIX-targeted PET/CT imaging in solid tumors
Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.
-
Immune cell therapy for advanced clear cell kidney cancer
This study tests a patient's own tumor-infiltrating lymphocytes (TIL) therapy, given after conditioning with chemotherapy and then interleukin-2, in adults with advanced clear cell renal cell carcinoma who have tried prior treatments.
-
Theranostic pair labeled PD-32766D/T in CA9-positive clear cell kidney cancer
This study tests a matching diagnostic agent PD-32766D and a therapeutic agent PD-32766T in adults with CA9-expressing clear cell renal cell carcinoma to see if the treatment is safe and shows signs of effect.
-
LNK001 CAR T therapy in advanced clear cell kidney cancer
This study tests a CAR T-cell therapy called LNK001 to see if it can help people with advanced clear cell renal cell carcinoma after other treatments.
-
Neoadjuvant immunotherapy with botensilimab and balstilimab for high-risk non-metastatic clear cell RCC
This trial tests whether giving botensilimab and balstilimab before kidney tumor surgery is safe and helps patients with high‑risk non‑metastatic clear cell RCC proceed to nephrectomy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.